Most Read Articles
Jairia Dela Cruz, 6 days ago
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 22 Jun 2018

“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.

Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.

Relapse may contribute to antipsychotic treatment resistance

03 Dec 2018

Relapse following effective treatment of the first episode of schizophrenia may reduce or delay antipsychotic treatment response, a recent study has shown.

Patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria were included: referral to the First-Episode Psychosis Program between 2003 and 2013; treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; positive symptom remission; subsequent relapse (ie, second episode) in association with nonadherence; and reintroduction of antipsychotic treatment with the same agent used to achieve response in the first episode.

Outcomes used as an index of antipsychotic treatment response were as follows: changes in the brief psychiatric rating scale total and positive symptom scores and number of patients who achieved positive symptom remission and 20- and 50-percent response.

One hundred thirty patients were analysed, and all of them took the same antipsychotic drug in both episodes. However, significant episode-by-time interactions occurred for all outcomes of antipsychotic treatment response over 1 year in favour of the first vs the second episode (50-percent response rate: 48.7 percent vs 10.4 percent at week 7; 88.2 percent vs 27.8 percent at week 27, respectively).

There were significantly higher antipsychotic doses in the second vs the first episode, but the results remained unchanged after adjusting for antipsychotic dose.

“Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 22 Jun 2018

“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.

Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.